Prime Medicine Stock (NASDAQ:PRME)
Previous Close
$1.32
52W Range
$1.11 - $8.27
50D Avg
$2.09
200D Avg
$3.45
Market Cap
$162.64M
Avg Vol (3M)
$1.33M
Beta
1.89
Div Yield
-
PRME Company Profile
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
PRME Performance
Peer Comparison
| Ticker | Company |
|---|---|
| IPSC | Century Therapeutics, Inc. |
| DNA | Ginkgo Bioworks Holdings, Inc. |
| OCEA | Ocean Biomedical, Inc. |
| EDIT | Editas Medicine, Inc. |
| RLAY | Relay Therapeutics, Inc. |
| BEAM | Beam Therapeutics Inc. |
| RPRX | Royalty Pharma plc |
| VERV | Verve Therapeutics, Inc. |
| CRSP | CRISPR Therapeutics AG |
| SANA | Sana Biotechnology, Inc. |
| NTLA | Intellia Therapeutics, Inc. |
| BPMC | Blueprint Medicines Corporation |
| CRBU | Caribou Biosciences, Inc. |